
for the treatment of burn wounds (including superficial second degree, or deepsecond degree burn wounds), residual small wounds, skin donor site wounds, chronic ulcers and other fresh and old skin wounds. "Highlights: 1,The sequence and conformation of the amino acids in our rhEGF are homologous to that in Human EGF. This makes our product high activity and high safety. 2, The discovery awarded for Nobel Prize 3, High safety— the sequence and conformation of the amino acids in our rhEGF product are homologous to that in Human EGF. 4,Higher efficacy with specific bioactivity: specific bioactivity in: our product ≥1*106IU/mg VS CP standards ≥0.5*106IU/mg 5, Excellent biocompatibility to safely use: powder, can be prepared with proper concentrations according to actual situation. 6, Rapid healing and repair, lower complication rate, without adverse reaction reported Registration Dossiers:non-clinical & clinical part, drug substance part and drug product part."